Impression Cytologic Evaluation of the Conjunctiva in Patients Treated with Topical 1% Voriconazole
- PMID: 38008933
- PMCID: PMC10895164
- DOI: 10.4274/tjo.galenos.2023.20268
Impression Cytologic Evaluation of the Conjunctiva in Patients Treated with Topical 1% Voriconazole
Abstract
Objectives: The aim of the present study was to evaluate any conjunctival metaplastic changes by impression cytology in patients who underwent topical 1% voriconazole treatment for severe fungal keratitis.
Materials and methods: The study was conducted at Ege University Faculty of Medicine, Departments of Ophthalmology and Medical Pathology. Patients who were treated with 1% topical voriconazole for fungal keratitis for at least 3 months were included. The used topical voriconazole treatment was initiated as one drop every hour and was tapered according to clinical improvement in all patients. Treatment was continued 4 times a day for at least 3 months. Impression cytology samples were collected at least 3 months after cessation of topical voriconazole from the affected eyes and from the fellow eyes as a control group. Collected specimens were transferred to the pathology department for evaluation and grading (Nelson’s grading system).
Results: The mean age of the patients was 57.68±17.32 years (range, 22-87 years). The impression cytology grade of the inferior bulbar conjunctiva was 1.73±0.77 (range, 0-3) in the study group and 1.19±0.98 (range, 0-3) in the control group (p=0.03). The impression cytology grade of the temporal bulbar conjunctiva was 1.69±0.73 (range, 0-3) in the study group and 1.15±0.88 (range, 0-3) in the control group (p=0.02). The impression cytology grades of the nasal and superior bulbar conjunctiva did not differ statistically (p values 0.13 and 0.17, respectively).
Conclusion: Topical voriconazole is an effective broad-spectrum antifungal drug, but it induces conjunctival squamous metaplasia. Clinicians should be aware of this possible side effect of topical voriconazole and should carefully evaluate the conjunctiva of treated patients at each visit to detect possible metaplastic changes.
Keywords: metaplasia; voriconazole; Fungal keratitis; impression cytology.
©Copyright 2024 by the Turkish Ophthalmological Association / Turkish Journal of Ophthalmology published by Galenos Publishing House.
Conflict of interest statement
Conflict of Interest: No conflict of interest was declared by the authors.
Similar articles
-
Medical interventions for fungal keratitis.Cochrane Database Syst Rev. 2015 Apr 9;2015(4):CD004241. doi: 10.1002/14651858.CD004241.pub4. Cochrane Database Syst Rev. 2015. PMID: 25855311 Free PMC article.
-
Evaluation of topical 1% posaconazole therapy in refractory fungal keratitis.Indian J Ophthalmol. 2025 Jan 1;73(1):64-72. doi: 10.4103/IJO.IJO_1811_24. Epub 2024 Dec 23. Indian J Ophthalmol. 2025. PMID: 39723856 Free PMC article.
-
Prophylactic non-steroidal anti-inflammatory drugs for the prevention of macular oedema after cataract surgery.Cochrane Database Syst Rev. 2016 Nov 1;11(11):CD006683. doi: 10.1002/14651858.CD006683.pub3. Cochrane Database Syst Rev. 2016. PMID: 27801522 Free PMC article.
-
Comparative Evaluation of Topical Monotherapy (Natamycin or Natasol) and Combination Therapy (Natamycin and Voriconazole) in Mild-Moderate Fungal Keratitis.Cornea. 2024 Sep 20;44(8):970-975. doi: 10.1097/ICO.0000000000003704. Cornea. 2024. PMID: 39312711 Clinical Trial.
-
Topical pharmacologic interventions versus placebo for epidemic keratoconjunctivitis.Cochrane Database Syst Rev. 2022 Mar 3;3(3):CD013520. doi: 10.1002/14651858.CD013520.pub2. Cochrane Database Syst Rev. 2022. PMID: 35238405 Free PMC article.
References
-
- Herbrecht R. Voriconazole: Therapeutic review of a new azole antifungal. Expert Rev Anti Infect Ther. 2004;2:485–497. - PubMed
-
- Hariprasad SM, Mieler WF, Lin TK, Sponsel WE, Graybill JR. Voriconazole in the treatment of fungal eye infections: a review of current literature. Br J Ophthalmol. 2008;92:871–878. - PubMed
-
- Ziakas PD, Kourbeti IS, Mylonakis E. Systemic antifungal prophylaxis after hematopoietic stem cell transplantation: a meta-analysis. Clin Ther. 2014;36:292–306. - PubMed
-
- Husain S, Paterson DL, Studer S, Pilewski J, Crespo M, Zaldonis D, Shutt K, Pakstis DL, Zeevi A, Johnson B, Kwak EJ, McCurry KR. Voriconazole prophylaxis in lung transplant recipients. Am J Transplant. 2006;6:3008–3016. - PubMed
-
- Sun CQ, Lalitha P, Prajna NV, Karpagam R, Geetha M, O’Brien KS, Oldenburg CE, Ray KJ, McLeod SD, Acharya NR, Lietman TM Mycotic Ulcer Treatment Trial Group. Association between in vitro susceptibility to natamycin and voriconazole and clinical outcomes in fungal keratitis. Ophthalmology. 2014;121:1495–1500. - PMC - PubMed
MeSH terms
Substances
LinkOut - more resources
Full Text Sources